The Discovery
One of the most unexpected findings in modern oncology came from several research groups simultaneously: patients with cancer who responded to immune checkpoint inhibitors (ICIs) — drugs like pembrolizumab, nivolumab, and ipilimumab — had systematically different gut microbiomes from non-responders. This observation, first published in Science in 2018 by Gopalakrishnan, Routy, and Matson in three parallel studies, suggested that the microbiome might be a modifiable determinant of cancer treatment outcomes.
The Evidence
In melanoma patients receiving anti-PD-1 therapy, responders were enriched in Faecalibacterium prausnitzii, Ruminococcaceae, and Akkermansia muciniphila, while non-responders showed higher Bacteroidales abundance. Crucially, these were not merely observational findings: when stool from responding patients was transplanted into germ-free or antibiotic-treated mice bearing tumours, the mice showed enhanced anti-tumour immunity and improved ICI response. Stool from non-responders did not produce this effect.
Mechanisms
The microbiome modulates ICI efficacy through several pathways. SCFA production (particularly butyrate) enhances effector T cell function and modulates the ratio of effector to regulatory T cells in the tumour microenvironment. Microbial antigens can prime immune cells that cross-react with tumour neoantigens — a phenomenon called molecular mimicry. Microbial metabolites influence dendritic cell maturation and antigen presentation. And the overall inflammatory tone set by the gut microbiome determines the baseline activation state of the immune system that ICIs aim to unleash.
Antibiotics: The Iatrogenic Problem
Retrospective studies consistently show that antibiotic use within 30 to 60 days before or during ICI treatment is associated with significantly reduced overall survival and progression-free survival — across multiple cancer types. This finding has prompted oncologists to reconsider routine perioperative and prophylactic antibiotic use in patients planned for immunotherapy, advocating for antimicrobial stewardship as an integral part of oncological care.
FMT in Oncology
Early-phase clinical trials have explored FMT as a strategy to convert ICI non-responders into responders. A landmark 2021 Science paper demonstrated that FMT from ICI-responding melanoma patients into non-responding patients produced clinical responses in a subset — with corresponding shifts in recipient microbiome composition and tumour-infiltrating lymphocyte populations. While these results are preliminary and involve small patient numbers, they represent a proof of concept for microbiome-based oncological intervention.
Future Directions
Larger, randomised trials of FMT and defined microbial consortia in ICI therapy are underway. Microbiome profiling before immunotherapy initiation may become a standard predictive biomarker. Dietary interventions (high-fibre diets enriched in SCFA precursors) are being tested as adjuncts to ICI therapy. The integration of microbiome science into oncology represents one of the most transformative potential applications of gut microbiome research.